Evidence map›Paper›PMID 31598339›Full record

ArticleJournal of breast cancer2019

Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen.

Soo Yeon Baek, Ji Yeong Kwon, Young Joo Lee, Sung-Chan Gwark, Sae Byul Lee, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Sung-Bae Kim and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Soo Yeon BaekDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0003-2026-0603
Ji Yeong KwonDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-8206-3811
Young Joo LeeDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-5352-8093
Sung-Chan GwarkDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0003-2511-2976
Sae Byul LeeDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0002-3370-6937
Jisun KimDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0002-4884-6107
Il Yong ChungDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-5271-8530
Beom Seok KoDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-7831-7874
Hee Jeong KimDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0002-4509-953X
Sung-Bae KimDepartment of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-5588-8332
Seung Do AhnDepartments of Radiation Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0003-4153-4191
Gyungyub GongDepartment of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-5743-0712
Byung Ho SonDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0002-6757-0388
Sei-Hyun AhnDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0002-6705-7867
Jong Won LeeDepartment of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-7875-1603
Ulsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe extension of endocrine therapy beyond 5 years for recurrence-free survivors of breast cancer improves survival; however, the issue on how to clinically identify appropriate candidates remains controversial. This study aimed to identify prognostic factors for breast-cancer-specific mortality in patients who have had 5 years of tamoxifen treatment and categorize subgroups based on the risk of death using combinations of these prognostic factors to assist in the clinical decision to perform further endocrine therapy.

methodsIn total, 3,158 patients with breast cancer were enrolled. Breast cancer-specific survival rates after 5 years of tamoxifen treatment were calculated, and associated prognostic factors were analyzed using a Cox proportional-hazards model.

resultsAn age extreme at diagnosis (i.e., < 40 or ≥ 60 years), tumor size > 2 cm, and positive lymphovascular invasion were robust independent prognostic factors for late breast cancer-specific death in tamoxifen-treated patients (hazard ratio [HR] = 2.162, 1.739, and 1.993;

conclusionThis new risk stratification system for late mortality in breast cancer can be used to identify the right candidates for extended endocrine therapy after 5 years of tamoxifen treatment.

Indexed as

Breast neoplasmsCancer survivorsPrognosisTamoxifen

Identifiers

PMID31598339
PMCPMC6769394
OpenAlexW2966753069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.